GlassScriptPhysician profile
Morgan T Dean
NPI 1659846921
$4,171.38
in general payments reported to CMS, 2019-2025
27 companies · $567 in 2025
The $567 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,388 · 2022: $950 · 2023: $669 · 2024: $598 · 2025: $567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.94 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $568.70 | 2021-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.17 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $316.40 | 2021-2024 | Austedo, Uzedy |
| Vanda Pharmaceuticals INC. | $260.78 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $222.35 | 2021-2023 | Trintellix |
| Alkermes, INC. | $190.17 | 2021-2024 | Aristada, Lybalvi |
| Corium, LLC | $185.48 | 2022-2023 | Azstarys |
| Lundbeck LLC | $137.33 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $124.86 | 2021 | |
| Neurocrine Biosciences, INC. | $72.09 | 2021-2022 | |
| Axsome Therapeutics, INC. | $54.59 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $52.03 | 2022-2023 | Spravato |
| Eisai INC. | $44.22 | 2021 | |
| Almatica Pharma LLC | $44.21 | 2022-2025 | Teriparatide, Loreev Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $42.35 | 2021 | |
| Amgen INC. | $36.90 | 2024-2025 | Repatha, Otezla, Repatha |
| Exact Sciences Corporation | $34.52 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $32.32 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $24.18 | 2023 | Hemosphere |
| Dexcom, INC. | $23.76 | 2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $23.74 | 2025 | Mounjaro, Zepbound |
| Inspire Medical Systems, INC. | $19.65 | 2025 | Inspire |
| Supernus Pharmaceuticals, INC. | $17.32 | 2021 | |
| Bausch Health US, LLC | $16.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2025 | |
| Adlon Therapeutics L.P. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Dean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.